#CancerMoonshot today will not only be about glioblastoma, but about the horrible DIPG (diffuse intrinsic pontine glioma) occuring in children and young adults.
You know who got their PIP plan approved last year by the MHRA in the UK?
You know who ANNOUNCED a new center of cancer excellence in Sutton in the UK two months ago, 130 miles from Sawston, focusing on DIPG?
You know who donated 2.5 million pounds to the center and that Hugh Adams works for them and have helped NWBO meeting british politicians and he wrote the "Pathway to a Cure" report, where politicians urges MHRA and NICE to get DCVax-L to patients?
SAME DAY MHRA announced this
"This new funding will accelerate the delivery of cutting-edge treatments like cancer vaccines"
One week later the MHRA announced this.
The new Quarterly SEC filing says
"We plan to work on preparations for Phase II trials of DCVax-Direct as resources permit."
You know NWBO already had planned DCVax-Direct trials in 2019 targeting DIPG?
Is the new MHRA draft on external control arms a DIRECT outcome of the APPGBT’s years-long glioblastoma inquiries and the Pathway to a Cure recommendations?
And was the DCVax-L trial the precursor that proved the case?
Diving into it ... it seems so.
Yes!
2/
In May 2025, the UK’s MHRA released a draft guideline:
“Using External Control Arms Based on Real-World Data to Support Regulatory Decisions.”
To most, this looks like a global trend.
But looking closer, it seems directly influenced by the DCVax-L trial.
3/
The MHRA draft came 2 years after the UK Parliament’s Pathway to a Cure report, which called for:
No placebos in brain tumour trials
Use of real-world external controls
Regulatory flexibility for cell therapies like DCVax-L
Let’s clarify a common question about $NWBO's Flaskworks Eden rollout:
“If the Grade C labs weren’t built at the time of the MAA… how close are we really to Eden manufacturing?”
3/11
✅ First, Advent BioServices already has Grade C cleanrooms in place at the Sawston facility.
These are licensed and actively used under MHRA and HTA for GMP-grade manual manufacturing.
Flaskworks Eden is designed to run within these existing Grade C environments.